The assay is the easy part

Running a PGx panel is a solved problem for most CLIA laboratories. The moment you have to interpret the result, though, the scope explodes. A single star-allele call has to be mapped to a phenotype, matched against every relevant drug, graded on current evidence, and rendered into something a prescriber can act on. That interpretation layer is the real product — and it never stops needing work.

Building in-house means owning a permanent evidence pipeline. You have to curate and reconcile CPIC guidelines, FDA pharmacogenomic biomarker labeling, DailyMed prescribing data, and DPWG recommendations across dozens of genes and hundreds of drugs — then keep that graph accurate every time a source is revised.

The cost that isn’t on the quote

The build estimate people write down covers software. The cost that actually hurts is ongoing: the scientific and medical labor required to keep interpretations correct month after month, long after the initial system ships.

A credible in-house program has to permanently staff three standing functions, so the real budget covers:

• curation

• review

• software

Every one of those is a standing line item, not a one-time build cost — and each carries clinical liability if it lapses.

Guidelines move, and so do patients

PGx evidence is not static. CPIC revises guidelines, the FDA updates label language, and new gene-drug pairs reach actionable status. A report that was correct at sign-out can quietly drift out of date.

Handling that in-house means building surveillance for every source, a way to detect which past reports are affected, and a workflow to route those cases back to a medical director for re-review. Most labs discover this requirement only after the first guideline change leaves older reports stale.

Someone still has to sign it out

A PGx report is a clinical document. However the interpretation is generated, a qualified medical director has to review and sign out the result — and that review has to be fast enough not to bottleneck turnaround.

In-house, that means designing an assisted-review workflow where automation flags gene-drug interactions but a clinician always makes the call. Building that balance — enough automation to scale, never so much that software decides — is its own engineering and compliance project.

Delivery is where it gets real

A PDF emailed to a physician is not a reporting program. Real adoption depends on results landing inside the systems clinicians already use.

That means FHIR R4, HL7 ORU, CDS Hooks, and SMART on FHIR — plus patient-facing access.

Each interface is a standard with its own conformance, versioning, and testing burden, and every EHR connection has to be built and maintained. Underneath it all sits multi-tenant security: HIPAA and GDPR compliance, encryption in transit and at rest, RBAC, strict tenant isolation, and a full audit trail.

decision = model.predict(input_data)
execute(decision)

What a turnkey platform removes

A white-label platform like SignalPGx exists so a lab doesn’t have to rebuild any of that. The lab runs the genotyping; SignalPGx turns VCF, CSV, Agena MassARRAY, or array results into branded, physician-reviewed reports delivered into the EHR.

The recurring work you would otherwise own is absorbed, including:

1. the multi-source evidence pipeline

2. guideline and medication surveillance

3. standards-based EHR delivery

Evidence is graded against CPIC, FDA labeling, DailyMed, and DPWG across roughly 50+ pharmacogenes and about 950 medications, reconciled from more than 15 curated sources. SignalAI assists interpretation and flags gene-drug interactions, but your medical director reviews and signs out every report. Living Reports re-analyze automatically when guidelines or a patient’s medications change, routing flagged cases back for a fresh medical-director review.

Conclusion

The build question is rarely “can we?” — it’s “can we keep doing it, correctly, forever?”

For most labs, buying converts a permanent scientific, clinical, and engineering commitment into transparent per-report pricing and a live program in about a week. SignalPGx is not a diagnostic test and never replaces the physician — final prescribing stays with the ordering clinician — but it removes the hidden, ongoing cost of doing PGx reporting well.